Today: 8 June 2026
QBE share price jumps 7% after FY25 profit beat, dividend hike and Swiss Re deal — what’s next
20 February 2026
2 mins read

QBE share price jumps 7% after FY25 profit beat, dividend hike and Swiss Re deal — what’s next

Sydney, Feb 20, 2026, 17:34 AEDT — After-hours

  • QBE jumped 7.1%, settling at A$21.48, after the insurer delivered better-than-expected full-year numbers and lifted its final dividend.
  • The group has also struck a deal to offload its global trade credit and surety business, handing it over to Swiss Re Corporate Solutions.
  • Attention turns to March dividend dates next, with QBE’s AGM and first-quarter update lined up for May.

QBE Insurance Group (ASX:QBE) shares climbed 7.1% to finish at A$21.48 on Friday. The insurer turned in a stronger full-year profit and bumped up its dividend.

Investors have been edgy over claims costs—natural catastrophes in particular—and the effect on insurers’ margins hasn’t gone unnoticed. QBE’s release drops right in the thick of Australia’s reporting season, a period where capital strength and dividend moves can swing prices sharply.

Insurers are still adjusting their portfolios to manage volatility. QBE’s specialty unit sale fits the pattern. Now, the focus shifts to where the proceeds go: reinvestment, returns to shareholders, or cost cuts.

QBE posted a statutory net profit after tax of US$2.157 billion for 2025, with adjusted net profit reaching US$2.132 billion. Premium growth and higher investment income played a role. The combined operating ratio dropped to 91.9% from last year’s 93.1%. Net catastrophe claims ended up at US$751 million, well under the US$1.16 billion allowance. The insurer announced a final dividend of 78 Australian cents per share, bringing the total for the year to 109 cents. Guidance for 2026 remains unchanged: a combined operating ratio around 92.5% and mid-single-digit premium growth. “QBE delivered strong performance in 2025, exceeding our financial plan,” CEO Andrew Horton said. ASX Announcements

The shares jumped up to 8.5% to hit A$21.76 early on—a level not seen since early September—but later slipped from those highs by the close.

QBE rolled out its results and, at the same time, announced a deal to sell its Global Trade Credit and Surety business to Swiss Re Corporate Solutions. The transaction leaves out its French Bonds operation. “Our decision to divest … enables the reallocation of capital and resources towards growth opportunities,” said Horton. QBE Australia Pacific CEO Sue Houghton pointed to Swiss Re’s “fresh perspective and strong intent.” QBE DEV

Swiss Re said the acquired business should bring in around US$200 million a year in revenue, broadening its credit and surety offering. “This acquisition marks an important milestone,” Swiss Re Corporate Solutions CEO Ivan Gonzalez said. He noted financial terms weren’t being released, and said the deal still needs several months for approvals. swissre.com

Nigel Pittaway at Citi described QBE’s numbers as “a strong result,” highlighting gains in premiums and a combined operating ratio that beat forecasts—despite pressure from commissions and expenses. News.com.au

But this is insurance—surprises tend to show up. A tougher stretch for catastrophe losses, increased pricing pressure in crowded market segments, or sluggish investment performance could sap earnings strength and put the sustainability of that dividend boost in question.

QBE shares are set to trade ex-dividend on March 5. Investors on the books by March 6 will be eligible for the final payout, which lands April 17. Then on May 8, shareholders can expect both the AGM and the first-quarter update.

Stock Market Today

  • Indian Stock Market July 8: Cautious Start Amid Middle East Tensions
    June 8, 2026, 9:21 AM EDT. Indian stocks are poised for a cautious open on June 8, impacted by rising Middle East tensions and a global market selloff. The GIFT Nifty index fell over 1%, as Asian markets including South Korea and Japan declined sharply, signaling increased investor risk aversion. Higher crude oil prices and a rebound in gold indicate a shift towards defensive assets. Investors will watch key domestic developments in companies like TVS Motor, RailTel, KNR Constructions, Creative Newtech, Amber Enterprises, and Ixigo. Fundraising activities at Zee, ASM Technologies, and Gujarat Themis, along with regulatory issues at Yes Bank, 5Paisa, and Reliance Infrastructure, will also remain in focus.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Seek Limited share price drops as ASX:SEK flags Employment Hero exit and tightens FY26 outlook
Previous Story

Seek Limited share price drops as ASX:SEK flags Employment Hero exit and tightens FY26 outlook

Tesco share price nudges toward 52-week high after UK retail sales jump — what to watch next
Next Story

Tesco share price nudges toward 52-week high after UK retail sales jump — what to watch next

Go toTop